首页> 外文期刊>Frontiers in Pediatrics >Digital Health for Supporting Precision Medicine in Pediatric Endocrine Disorders: Opportunities for Improved Patient Care
【24h】

Digital Health for Supporting Precision Medicine in Pediatric Endocrine Disorders: Opportunities for Improved Patient Care

机译:用于支持儿科内分泌疾病精密药物的数字健康:改善患者护理的机会

获取原文
       

摘要

Digitalization of healthcare delivery is rapidly fostering development of precision medicine. Multiple digital technologies, known as telehealth or eHealth tools, are guiding individualized diagnosis and treatment for patients, and can contribute significantly to the objectives of precision medicine. From a basis of “one-size-fits-all” healthcare, precision medicine provides a paradigm shift to deliver a more nuanced and personalized approach. Genomic medicine utilizing new technologies can provide precision analysis of causative mutations, with personalized understanding of mechanisms and effective therapy. Education is fundamental to the telehealth process, with artificial intelligence (AI) enhancing learning for healthcare professionals and empowering patients to contribute to their care. The Gulf Cooperation Council (GCC) region is rapidly implementing telehealth strategies at all levels and a workshop was convened to discuss aspirations of precision medicine in the context of pediatric endocrinology, including diabetes and growth disorders, with this paper based on those discussions. GCC regional investment in AI, bioinformatics and genomic medicine, is rapidly providing healthcare benefits. However, embracing precision medicine is presenting some major new design, installation and skills challenges. Genomic medicine is enabling precision and personalization of diagnosis and therapy of endocrine conditions. Digital education and communication tools in the field of endocrinology include chatbots, interactive robots and augmented reality. Obesity and diabetes are a major challenge in the GCC region and eHealth tools are increasingly being used for management of care. With regard to growth failure, digital technologies for growth hormone (GH) administration are being shown to enhance adherence and response outcomes. While technical innovations become more affordable with increasing adoption, we should be aware of sustainability, design and implementation costs, training of HCPs and prediction of overall healthcare benefits, which are essential for precision medicine to develop and for its objectives to be achieved.
机译:数字化医疗保健交付是迅速促进精密医学的发展。多种数字技术,称为远程医疗或eHealth工具,正在引导患者的个性化诊断和治疗,并且可以对精密药物的目标进行显着贡献。从“单尺寸适合 - 所有”医疗保健的基础,精密药物提供了一种范式转变,以提供更细致和个性化的方法。利用新技术的基因组医学可以提供致病性突变的精确分析,具有个性化对机制和有效治疗的理解。教育是对远程健康进程的基础,具有人工智能(AI)加强医疗保健专业人士的学习,并赋予患者促进其护理。海湾合作委员会(GCC)地区正在迅速实施各级的远程健康战略,并召开讲习班,讨论小儿科内分泌学中的精密药物的愿望,包括糖尿病和生长障碍,本文根据这些讨论。 GCC区域投资AI,生物信息学和基因组医学,正在迅速提供医疗保健效益。然而,拥抱精密药品呈现出一些主要的新设计,安装和技能挑战。基因组医学是能够精确和个性化内分泌条件的诊断和治疗。内分泌领域的数字教育和通信工具包括聊天,交互式机器人和增强现实。肥胖症和糖尿病是GCC地区的主要挑战,eHealth工具越来越多地用于管理护理。关于生长衰竭,正在显示出生长激素(GH)给药的数字技术来增强依从性和反应结果。虽然技术创新随着采纳的增加而变得更加负担得起,但我们应该了解可持续性,设计和实施成本,HCP培训和对整体医疗保健福利的预测,这对于精密药业发展和实现其目标是必不可少的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号